Gene fusions in vascular tumors and their underlying molecular mechanisms

References

• Selleri L, Hermanson GG, Eubanks JH, et al. Molecular localization of the t(11;22)(q24;q12) translocation of Ewing sarcoma by chromosomal in situ suppression hybridization. Proc Natl Acad Sci U S A. 1991;88(3):887–891.
   PubMed Web of Science ®Google Scholar
• Lam SW, IJzendoorn DGP, Cleton-Jansen AM, et al. Molecular Pathology of Bone Tumors. J Mol Diagn. 2019;21(2):171–182.
   PubMed Web of Science ®Google Scholar
• WHO classification of tumours of soft tissue and bone. WHO classification of Tumours Editiorial Board. 5th edition Vol. 3 Lyon France: IARC; 2020.
   Google Scholar
• Mitelman F, Johansson B, Mertens F. The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer. 2007;7(4):233–245.
   PubMed Web of Science ®Google Scholar
• Roukos V, Misteli T. The biogenesis of chromosome translocations. Nat Cell Biol. 2014;16(4):293–300.
   PubMed Web of Science ®Google Scholar
• Delattre O, Zucman J, Plougastel B, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature. 1992;359(6391):162–165.
   PubMed Web of Science ®Google Scholar
• Sand LG, Szuhai K, Hogendoorn PC. Sequencing Overview of Ewing Sarcoma: a Journey across Genomic, Epigenomic and Transcriptomic Landscapes. Int J Mol Sci. 2015;16(7):16176–16215.
   PubMed Web of Science ®Google Scholar
• Riggi N, Suva ML, Stamenkovic I. Ewing’s Sarcoma. N Engl J Med. 2021;384(2):154–164.
   PubMed Web of Science ®Google Scholar
• Oliveira AM, Hsi BL, Weremowicz S, et al. USP6 (Tre2) fusion oncogenes in aneurysmal bone cyst. Cancer Res. 2004;64(6):1920–1923.
   PubMed Web of Science ®Google Scholar
• Lamerato-Kozicki AR, Helm KM, Jubala CM, et al. Canine hemangiosarcoma originates from hematopoietic precursors with potential for endothelial differentiation. Exp Hematol. 2006;34(7):870–878.
   PubMed Web of Science ®Google Scholar
• Kakiuchi-Kiyota S, Crabbs TA, Arnold LL, et al. Evaluation of expression profiles of hematopoietic stem cell, endothelial cell, and myeloid cell antigens in spontaneous and chemically induced hemangiosarcomas and hemangiomas in mice. Toxicol Pathol. 2013;41(5):709–721.
   PubMed Web of Science ®Google Scholar
• Liau JY, Tsai JH, Lan J, et al. GNA11 joins GNAQ and GNA14 as a recurrently mutated gene in anastomosing hemangioma. Virchows Arch. 2020;476(3):475–481.
   PubMed Web of Science ®Google Scholar
• Raamsdonk CD, Bezrookove V, Green G, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature. 2009;457(7229):599–602.
   PubMed Web of Science ®Google Scholar
• Landis CA, Masters SB, Spada A, et al. GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature. 1989;340(6236):692–696.
   PubMed Web of Science ®Google Scholar
• Rao VV, Schnittger S, Hansmann I. G protein Gs alpha (GNAS 1), the probable candidate gene for Albright hereditary osteodystrophy, is assigned to human chromosome 20q12-q13.2. Genomics. 1991;10(1):257–261.
   PubMed Web of Science ®Google Scholar
• Zhu G, Benayed R, Ho C, et al. Diagnosis of known sarcoma fusions and novel fusion partners by targeted RNA sequencing with identification of a recurrent ACTB-FOSB fusion in pseudomyogenic hemangioendothelioma. Mod Pathol. 2019;32(5):609–620.
   PubMed Web of Science ®Google Scholar
• Tsukamoto Y, Futani H, Watanabe T, et al. Two cases of WWTR1-CAMTA-1 fusion-positive epithelioid hemangioendotheliomas with extremely different outcomes. Hum Pathol. 2018;14:25–32.
   PubMed Web of Science ®Google Scholar
• Papke DJ Jr., Hornick JL. What is new in endothelial neoplasia? Virchows Arch. 2020;476(1):17–28.
   PubMed Web of Science ®Google Scholar
• Evans HL, Raymond AK, Ayala AG. Vascular tumors of bone: a study of 17 cases other than ordinary hemangioma, with an evaluation of the relationship of hemangioendothelioma of bone to epithelioid hemangioma, epithelioid hemangioendothelioma, and high-grade angiosarcoma. Hum Pathol. 2003;34(7):680–689.
   PubMed Web of Science ®Google Scholar
• Errani C, Zhang L, Sung YS, et al. A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. Genes Chromosomes Cancer. 2011;50(8):644–653.
   PubMed Web of Science ®Google Scholar
• Llamas-Velasco M, Kempf W, Cota C, et al. Multiple Eruptive Epithelioid Hemangiomas: a Subset of Cutaneous Cellular Epithelioid Hemangioma With Expression of FOS-B. Am J Surg Pathol. 2019;43(1):26–34.
   PubMed Web of Science ®Google Scholar
• Ortins-Pina A, Llamas-Velasco M, Turpin S, et al. FOSB immunoreactivity in endothelia of epithelioid hemangioma (angiolymphoid hyperplasia with eosinophilia). J Cutan Pathol. 2018;45(6):395–402.
   PubMed Web of Science ®Google Scholar
• Antonescu CR, Huang SC, Sung YS, et al. Novel GATA6-FOXO1 fusions in a subset of epithelioid hemangioma. Mod Pathol. 2020;34:934–941.
   Web of Science ®Google Scholar
• Huang SC, Zhang L, Sung YS, et al. Frequent FOS Gene Rearrangements in Epithelioid Hemangioma: a Molecular Study of 58 Cases With Morphologic Reappraisal. Am J Surg Pathol. 2015;39(10):1313–1321.
   PubMed Web of Science ®Google Scholar
• Bejjani F, Evanno E, Zibara K, et al. The AP-1 transcriptional complex: local switch or remote command? Biochim Biophys Acta Rev Cancer. 2019;1872(1):11–23.
   PubMed Web of Science ®Google Scholar
• Eijkelenboom A, Burgering BM. FOXOs: signalling integrators for homeostasis maintenance. Nat Rev Mol Cell Biol. 2013;14(2):83–97.
   PubMed Web of Science ®Google Scholar
• IJzendoorn DGP, Jong D, Romagosa C, et al. Fusion events lead to truncation of FOS in epithelioid hemangioma of bone. Genes Chromosomes Cancer. 2015;54(9):565–574.
   PubMed Web of Science ®Google Scholar
• Tsuda Y, Suurmeijer AJH, Sung YS, et al. Epithelioid hemangioma of bone harboring FOS and FOSB gene rearrangements: a clinicopathologic and molecular study. Genes Chromosomes Cancer. 2021;60(1):17–25.
   PubMed Web of Science ®Google Scholar
• Angel P, Karin M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta. 1991;1072(2–3):129–157.
   PubMed Web of Science ®Google Scholar
• Shaulian E, Karin M. AP-1 in cell proliferation and survival. Oncogene. 2001;20(19):2390–2400.
   PubMed Web of Science ®Google Scholar
• IJzendoorn DGP, Forghany Z, Liebelt F, et al., Functional analyses of a human vascular tumor FOS variant identify a novel degradation mechanism and a link to tumorigenesis. J Biol Chem. 2017;292(52):21282–21290. .
   PubMed Web of Science ®Google Scholar
• Antonescu CR, Chen HW, Zhang L, et al. ZFP36-FOSB fusion defines a subset of epithelioid hemangioma with atypical features. Genes Chromosomes Cancer. 2014;53(11):951–959.
   PubMed Web of Science ®Google Scholar
• Ooi LY, Goh JY, Kuick CH, et al. Intravascular epithelioid haemangioma of deep soft tissue with novel SETD1B-FOSB gene rearrangement. Pathology. 2020;23(2):270–273.
   PubMed Web of Science ®Google Scholar
• Curran T, Franza BR Jr. Fos and Jun: the AP-1 connection. Cell. 1988;55(3):395–397.
   PubMed Web of Science ®Google Scholar
• Yutsudo N, Kamada T, Kajitani K, et al. fosB-null mice display impaired adult hippocampal neurogenesis and spontaneous epilepsy with depressive behavior. Neuropsychopharmacology. 2013;38(5):895–906.
   PubMed Web of Science ®Google Scholar
• Li A, Dubey S, Varney ML, et al. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol. 2003;170(6):3369–3376.
   PubMed Web of Science ®Google Scholar
• Kiiveri S, Liu J, Arola J, et al. Transcription factors GATA-6, SF-1, and cell proliferation in human adrenocortical tumors. Mol Cell Endocrinol. 2005;233(1–2):47–56.
   PubMed Web of Science ®Google Scholar
• Caslini C, Capo-chichi CD, Roland IH, et al. Histone modifications silence the GATA transcription factor genes in ovarian cancer. Oncogene. 2006;25(39):5446–5461.
   PubMed Web of Science ®Google Scholar
• Kwei KA, Bashyam MD, Kao J, et al. Genomic profiling identifies GATA6 as a candidate oncogene amplified in pancreatobiliary cancer. PLoS Genet. 2008;4(5):e1000081.
   PubMed Web of Science ®Google Scholar
• Salonen J, Rajpert-De Meyts E, Mannisto S, et al. Differential developmental expression of transcription factors GATA-4 and GATA-6, their cofactor FOG-2 and downstream target genes in testicular carcinoma in situ and germ cell tumors. Eur J Endocrinol. 2010;162(3):625–631.
   PubMed Web of Science ®Google Scholar
• Zheng R, Blobel GA. GATA Transcription Factors and Cancer. Genes Cancer. 2010;1(12):1178–1188.
   PubMedGoogle Scholar
• Barr FG, Galili N, Holick J, et al. Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma. Nat Genet. 1993;3(2):113–117.
   PubMed Web of Science ®Google Scholar
• Galili N, Davis RJ, Fredericks WJ, et al. Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet. 1993;5(3):230–235.
   PubMed Web of Science ®Google Scholar
• Davis RJ, D’Cruz CM, Lovell MA, et al. Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. Cancer Res. 1994;54(11):2869–2872.
   PubMed Web of Science ®Google Scholar
• Potente M, Urbich C, Sasaki K, et al. Involvement of Foxo transcription factors in angiogenesis and postnatal neovascularization. J Clin Invest. 2005;115(9):2382–2392.
   PubMed Web of Science ®Google Scholar
• Furuyama T, Kitayama K, Shimoda Y, et al. Abnormal angiogenesis in Foxo1 (Fkhr)-deficient mice. J Biol Chem. 2004;279(33):34741–34749.
   PubMed Web of Science ®Google Scholar
• Daly C, Wong V, Burova E, et al. Angiopoietin-1 modulates endothelial cell function and gene expression via the transcription factor FKHR (FOXO1. Genes Dev. 2004;18(9):1060–1071.
   PubMed Web of Science ®Google Scholar
• Hung YP, Fletcher CDM, Hornick JL. FOSB is a Useful Diagnostic Marker for Pseudomyogenic Hemangioendothelioma. Am J Surg Pathol. 2017;41(5):596–606.
   PubMed Web of Science ®Google Scholar
• Trombetta D, Magnusson L, von Steyern FV, et al. Translocation t(7;19)(q22;q13)-a recurrent chromosome aberration in pseudomyogenic hemangioendothelioma? Cancer Genet. 2011;204(4):211–215.
   PubMed Web of Science ®Google Scholar
• Agaram NP, Zhang L, Cotzia P, et al. Expanding the Spectrum of Genetic Alterations in Pseudomyogenic Hemangioendothelioma With Recurrent Novel ACTB-FOSB Gene Fusions. Am J Surg Pathol. 2018;42(12):1653–1661.
   PubMed Web of Science ®Google Scholar
• Fittall MW, Mifsud W, Pillay N, et al. Recurrent rearrangements of FOS and FOSB define osteoblastoma. Nat Commun. 2018;9(1):2150.
   PubMed Web of Science ®Google Scholar
• Panagopoulos I, Gorunova L, Lobmaier I, et al. FOS-ANKH and FOS-RUNX2 Fusion Genes in Osteoblastoma. Cancer Genomics Proteomics. 2020;17(2):161–168.
   PubMed Web of Science ®Google Scholar
• Panagopoulos I, Lobmaier I, Gorunova L, et al. Fusion of the Genes WWTR1 and FOSB in Pseudomyogenic Hemangioendothelioma. Cancer Genomics Proteomics. 2019;16(4):293–298.
   PubMed Web of Science ®Google Scholar
• Bridge JA, Sumegi J, Royce T, et al. A novel CLTC-FOSB gene fusion in pseudomyogenic hemangioendothelioma of bone. Genes Chromosomes Cancer. 2021;60(1):38–42.
   PubMed Web of Science ®Google Scholar
• Thway K, Fisher C. Mesenchymal Tumors with EWSR1 Gene Rearrangements. Surg Pathol Clin. 2019;12(1):165–190.
   PubMedGoogle Scholar
• Walther C, Tayebwa J, Lilljebjorn H, et al. A novel SERPINE1-FOSB fusion gene results in transcriptional up-regulation of FOSB in pseudomyogenic haemangioendothelioma. J Pathol. 2014;232(5):534–540.
   PubMed Web of Science ®Google Scholar
• Hung YP, Fisch AS, Diaz-Perez JA, et al. Identification of EWSR1-NFATC2 Fusion in Simple Bone Cysts. Histopathology. 2020;78:849–856.
   PubMed Web of Science ®Google Scholar
• Joseph J, Wang WL, Patnana M, et al. Cytotoxic and targeted therapy for treatment of pseudomyogenic hemangioendothelioma. Clin Sarcoma Res. 2015;5(1):22.
   PubMedGoogle Scholar
• Ozeki M, Nozawa A, Kanda K, et al. Everolimus for Treatment of Pseudomyogenic Hemangioendothelioma. J Pediatr Hematol Oncol. 2017;39(6):e328–e331.
   PubMed Web of Science ®Google Scholar
• Gabor KM, Sapi Z, Tiszlavicz LG, et al. Sirolimus therapy in the treatment of pseudomyogenic hemangioendothelioma. Pediatr Blood Cancer. 2018;65(2):2.
   Web of Science ®Google Scholar
• IJzendoorn DGP, Sleijfer S, Gelderblom H, et al. Telatinib Is an Effective Targeted Therapy for Pseudomyogenic Hemangioendothelioma. Clin Cancer Res. 2018;24(11):2678–2687.
   PubMed Web of Science ®Google Scholar
• IJzendoorn DGP, Salvatori DCF, Cao X, et al. Vascular Tumor Recapitulated in Endothelial Cells from hiPSCs Engineered to Express the SERPINE1-FOSB Translocation. Cell Rep Med. 2020;1(9):100153.
   PubMedGoogle Scholar
• Requena L, Luis Diaz J, Manzarbeitia F, et al. Cutaneous composite hemangioendothelioma with satellitosis and lymph node metastases. J Cutan Pathol. 2008;35(2):225–230.
   PubMed Web of Science ®Google Scholar
• Perry KD, Al-Lbraheemi A, Rubin BP, et al. Composite hemangioendothelioma with neuroendocrine marker expression: an aggressive variant. Mod Pathol. 2017;30(10):1512.
   PubMed Web of Science ®Google Scholar
• Antonescu CR, Dickson BC, Sung YS, et al., Recurrent YAP1 and MAML2 Gene Rearrangements in Retiform and Composite Hemangioendothelioma. Am J Surg Pathol. 2020;44(12):1677–1684. .
   PubMed Web of Science ®Google Scholar
• Zema S, Pelullo M, Nardozza F, et al. Role of Mastermind-Like 1: a Journey Through the Main (Path)ways Between Development and Cancer. Front Cell Dev Biol. 2020;8:613557.
   PubMed Web of Science ®Google Scholar
• Chenevert J, Barnes LE, Chiosea SI. Mucoepidermoid carcinoma: a five-decade journey. Virchows Arch. 2011;458(2):133–140.
   PubMed Web of Science ®Google Scholar
• Alves-Guerra MC, Ronchini C, Capobianco AJ. Mastermind-like 1 Is a specific coactivator of beta-catenin transcription activation and is essential for colon carcinoma cell survival. Cancer Res. 2007;67(18):8690–8698.
   PubMed Web of Science ®Google Scholar
• Jin B, Shen H, Lin S, et al. The mastermind-like 1 (MAML1) co-activator regulates constitutive NF-kappaB signaling and cell survival. J Biol Chem. 2010;285(19):14356–14365.
   PubMed Web of Science ®Google Scholar
• Quaranta R, Pelullo M, Zema S, et al. Maml1 acts cooperatively with Gli proteins to regulate sonic hedgehog signaling pathway. Cell Death Dis. 2017;8(7):e2942.
   PubMed Web of Science ®Google Scholar
• Kim J, Kwon H, Shin YK, et al. MAML1/2 promote YAP/TAZ nuclear localization and tumorigenesis. Proc Natl Acad Sci U S A. 2020;117(24):13529–13540.
   PubMed Web of Science ®Google Scholar
• McElhinny AS, Li JL, Wu L. Mastermind-like transcriptional co-activators: emerging roles in regulating cross talk among multiple signaling pathways. Oncogene. 2008;27(38):5138–5147.
   PubMed Web of Science ®Google Scholar
• Wu L, Sun T, Kobayashi K, et al. Identification of a family of mastermind-like transcriptional coactivators for mammalian notch receptors. Mol Cell Biol. 2002;22(21):7688–7700.
   PubMed Web of Science ®Google Scholar
• Nam Y, Sliz P, Song L, et al. Structural basis for cooperativity in recruitment of MAML coactivators to Notch transcription complexes. Cell. 2006;124(5):973–983.
   PubMed Web of Science ®Google Scholar
• Wilson JJ, Kovall RA. Crystal structure of the CSL-Notch-Mastermind ternary complex bound to DNA. Cell. 2006;124(5):985–996.
   PubMed Web of Science ®Google Scholar
• Li Z, Zhao B, Wang P, et al. Structural insights into the YAP and TEAD complex. Genes Dev. 2010;24(3):235–240.
   PubMed Web of Science ®Google Scholar
• Valouev A, Weng Z, Sweeney RT, et al. Discovery of recurrent structural variants in nasopharyngeal carcinoma. Genome Res. 2014;24(2):300–309.
   PubMed Web of Science ®Google Scholar
• Kee HJ, Kim JR, Nam KI, et al. Enhancer of polycomb1, a novel homeodomain only protein-binding partner, induces skeletal muscle differentiation. J Biol Chem. 2007;282(10):7700–7709.
   PubMed Web of Science ®Google Scholar
• Antonescu CR, Sung YS, Chen CL, et al. Novel ZC3H7B-BCOR, MEAF6-PHF1, and EPC1-PHF1 fusions in ossifying fibromyxoid tumors--molecular characterization shows genetic overlap with endometrial stromal sarcoma. Genes Chromosomes Cancer. 2014;53(2):183–193.
   PubMed Web of Science ®Google Scholar
• Mendlick MR, Nelson M, Pickering D, et al. Translocation t(1;3)(p36.3;q25) is a nonrandom aberration in epithelioid hemangioendothelioma. Am J Surg Pathol. 2001;25(5):684–687.
   PubMed Web of Science ®Google Scholar
• Antonescu CR, Le Loarer F, Mosquera JM, et al. Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma. Genes Chromosomes Cancer. 2013;52(8):775–784.
   PubMed Web of Science ®Google Scholar
• Shibuya R, Matsuyama A, Shiba E, et al. CAMTA1 is a useful immunohistochemical marker for diagnosing epithelioid haemangioendothelioma. Histopathology. 2015;67(6):827–835.
   PubMed Web of Science ®Google Scholar
• Sharain RF, Gown AM, Greipp PT, et al. Immunohistochemistry for TFE3 lacks specificity and sensitivity in the diagnosis of TFE3-rearranged neoplasms: a comparative, 2-laboratory study. Hum Pathol. 2019;87:65–74.
   PubMed Web of Science ®Google Scholar
• Yang M, Liu E, Tang L, et al. Emerging roles and regulation of MiT/TFE transcriptional factors. Cell Commun Signal. 2018;16(1):31.
   PubMed Web of Science ®Google Scholar
• Tanas MR, Sboner A, Oliveira AM, et al. Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. Sci Transl Med. 2011;3(98):98ra82.
   PubMed Web of Science ®Google Scholar
• Park JA, Kwon YG. Hippo-YAP/TAZ signaling in angiogenesis. BMB Rep. 2018;51(3):157–162.
   PubMed Web of Science ®Google Scholar
• Taha Z, Janse van Rensburg HJ, Yang X. The Hippo Pathway: immunity and Cancer. Cancers (Basel). 2018;10(4):4.
   Web of Science ®Google Scholar
• Hong W, Guan KL. The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian Hippo pathway. Semin Cell Dev Biol. 2012;23(7):785–793.
   PubMed Web of Science ®Google Scholar
• Tanas MR, Ma S, Jadaan FO, et al., Mechanism of action of a WWTR1(TAZ)-CAMTA1 fusion oncoprotein. Oncogene. 2016;35(7):929–938. .
   PubMed Web of Science ®Google Scholar
• Shimo T, Nakanishi T, Nishida T, et al. Connective tissue growth factor induces the proliferation, migration, and tube formation of vascular endothelial cells in vitro, and angiogenesis in vivo. J Biochem. 1999;126(1):137–145.
   PubMed Web of Science ®Google Scholar
• Puls F, Niblett A, Clarke J, et al. YAP1-TFE3 epithelioid hemangioendothelioma: a case without vasoformation and a new transcript variant. Virchows Arch. 2015;466(4):473–478.
   PubMed Web of Science ®Google Scholar
• Jong B, Molenaar IM, Leeuw JA, et al. Cytogenetics of a renal adenocarcinoma in a 2-year-old child. Cancer Genet Cytogenet. 1986;21(2):165–169.
   PubMedGoogle Scholar
• Ladanyi M, Lui MY, Antonescu CR, et al. The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25. Oncogene. 2001;20(1):48–57.
   PubMed Web of Science ®Google Scholar
• Pogenberg V, Ogmundsdottir MH, Bergsteinsdottir K, et al. Restricted leucine zipper dimerization and specificity of DNA recognition of the melanocyte master regulator MITF. Genes Dev. 2012;26(23):2647–2658.
   PubMed Web of Science ®Google Scholar
• Hemesath TJ, Steingrimsson E, McGill G, et al. microphthalmia, a critical factor in melanocyte development, defines a discrete transcription factor family. Genes Dev. 1994;8(22):2770–2780.
   PubMed Web of Science ®Google Scholar
• Busca R, Berra E, Gaggioli C, et al. Hypoxia-inducible factor 1{alpha} is a new target of microphthalmia-associated transcription factor (MITF) in melanoma cells. J Cell Biol. 2005;170(1):49–59.
   PubMed Web of Science ®Google Scholar
• Fan Y, Lu H, Liang W, et al. Endothelial TFEB (Transcription Factor EB) Positively Regulates Postischemic Angiogenesis. Circ Res. 2018;122(7):945–957.
   PubMed Web of Science ®Google Scholar
• Rosenberg A, Agulnik M. Epithelioid Hemangioendothelioma: update on Diagnosis and Treatment. Curr Treat Options Oncol. 2018;19(4):19.
   PubMed Web of Science ®Google Scholar
• Verbeke SL, Jong D, Bertoni F, et al. Array CGH analysis identifies two distinct subgroups of primary angiosarcoma of bone. Genes Chromosomes Cancer. 2015;54(2):72–81.
   PubMed Web of Science ®Google Scholar
• Itakura E, Yamamoto H, Oda Y, et al. Detection and characterization of vascular endothelial growth factors and their receptors in a series of angiosarcomas. J Surg Oncol. 2008;97(1):74–81.
   PubMed Web of Science ®Google Scholar
• Antonescu CR, Yoshida A, Guo T, et al. KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. Cancer Res. 2009;69(18):7175–7179.
   PubMed Web of Science ®Google Scholar
• Huang SC, Zhang L, Sung YS, et al. Recurrent CIC Gene Abnormalities in Angiosarcomas: a Molecular Study of 120 Cases With Concurrent Investigation of PLCG1, KDR, MYC, and FLT4 Gene Alterations. Am J Surg Pathol. 2016;40(5):645–655.
   PubMed Web of Science ®Google Scholar
• Kawamura-Saito M, Yamazaki Y, Kaneko K, et al. Fusion between CIC and DUX4 up-regulates PEA3 family genes in Ewing-like sarcomas with t(4;19)(q35;q13) translocation. Hum Mol Genet. 2006;15(13):2125–2137.
   PubMed Web of Science ®Google Scholar
• Qi T, Qu Q, Li G, et al. Function and regulation of the PEA3 subfamily of ETS transcription factors in cancer. Am J Cancer Res. 2020;10(10):3083–3105.
   PubMed Web of Science ®Google Scholar
• Jimenez G, Shvartsman SY, Paroush Z. The Capicua repressor--a general sensor of RTK signaling in development and disease. J Cell Sci. 2012;125(Pt 6):1383–1391.
   PubMed Web of Science ®Google Scholar
• Fores M, Simon-Carrasco L, Ajuria L, et al. A new mode of DNA binding distinguishes Capicua from other HMG-box factors and explains its mutation patterns in cancer. PLoS Genet. 2017;13(3):e1006622.
   PubMed Web of Science ®Google Scholar
• Oh S, Shin S, Song H, et al. Relationship between ETS Transcription Factor ETV1 and TGF-beta-regulated SMAD Proteins in Prostate Cancer. Sci Rep. 2019;9(1):8186.
   PubMed Web of Science ®Google Scholar
• Meng D, Li Z, Ma X, et al. ETV5 overexpression contributes to tumor growth and progression of thyroid cancer through PIK3CA. Life Sci. 2020;253:117693.
   PubMed Web of Science ®Google Scholar
• Hua D, Chen B, Bai M, et al. PEA3 activates VEGF transcription in T47D and SKBR3 breast cancer cells. Acta Biochim Biophys Sin (Shanghai). 2009;41(1):63–68.
   PubMed Web of Science ®Google Scholar
• Keld R, Guo B, Downey P, et al. The ERK MAP kinase-PEA3/ETV4-MMP-1 axis is operative in oesophageal adenocarcinoma. Mol Cancer. 2010;9(1):313.
   PubMed Web of Science ®Google Scholar
• Kim JW, Ponce RK, Okimoto RA. Capicua in Human Cancer. Trends Cancer. 2021;7(1):77–86.
   PubMed Web of Science ®Google Scholar
• Boichard A, Wagner MJ, Kurzrock R. Angiosarcoma heterogeneity and potential therapeutic vulnerability to immune checkpoint blockade: insights from genomic sequencing. Genome Med. 2020;12(1):1.
   Web of Science ®Google Scholar
• Melincovici CS, Bosca AB, Susman S, et al. Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis. Rom J Morphol Embryol. 2018;59(2):455–467.
   PubMed Web of Science ®Google Scholar
• Lam SW, Cleven AHG, Kroon HM, et al. Utility of FOS as diagnostic marker for osteoid osteoma and osteoblastoma. Virchows Arch. 2020;476(3):455–463.
   PubMed Web of Science ®Google Scholar